Micreos Group Overview
- Year Founded
-
2005
- Status
-
Private
- Employees
-
6
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$24.4M
- Investors
-
6
Micreos Group General Information
Description
Developer of targeted antibacterial products designed to kill unwanted bacteria. The company's products specialize in phage technology that is set to replace antibiotics and can be used in health care and veterinary medicine unlocking a new therapeutic modality for people with chronic and recurring infections and inflammatory skin conditions, enabling physicians to treat diseases like eczema, rosacea, psoriasis, inflammatory acne, diabetic wound, and bloodstream infections.
Contact Information
Website
www.micreosgroup.comCorporate Office
- Soestdijkseweg Zuid 249
- 3721 AE Bilthoven
- Netherlands
Corporate Office
- Soestdijkseweg Zuid 249
- 3721 AE Bilthoven
- Netherlands
Micreos Group Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Later Stage VC | 25-Oct-2022 | $24.4M | Completed | Generating Revenue | ||
| 8. Later Stage VC | 30-Sep-2021 | Completed | Clinical Trials - Phase 2 | |||
| 7. Grant | 12-Nov-2019 | Completed | Clinical Trials - General | |||
| 6. Later Stage VC | 29-Mar-2019 | Completed | Clinical Trials - General | |||
| 5. Grant | 29-Mar-2019 | Completed | Clinical Trials - General | |||
| 4. Accelerator/Incubator | Completed | Clinical Trials - General | ||||
| 3. Later Stage VC | 18-Feb-2016 | Completed | Clinical Trials - General | |||
| 2. Later Stage VC | 22-Mar-2013 | Completed | Startup | |||
| 1. Later Stage VC | 23-May-2012 | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Micreos Group Comparisons
Industry
Financing
Details
Micreos Group Competitors (10)
One of Micreos Group’s 10 competitors is Gangagen Biotechnologies, a Venture Capital-Backed company based in Bangalore, India.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Gangagen Biotechnologies | Venture Capital-Backed | Bangalore, India | ||||
| UTILITY Therapeutics | Formerly VC-backed | Altrincham, United Kingdom | ||||
| Melinta Therapeutics | Private Equity-Backed | Parsippany, NJ | ||||
| Spero Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Ability Pharma | Private Equity-Backed | Cerdanyola, Spain |
Micreos Group Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Micreos Group Patents
Micreos Group Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026052743-A1 | Reduction of trans-epidermal water loss by a polypeptide with antibacterial properties | Pending | 04-Sep-2024 | ||
| EP-4486885-A1 | A chimeric endolysin polypeptide | Pending | 04-Mar-2022 | ||
| US-20250215410-A1 | A chimeric endolysin polypeptide | Pending | 04-Mar-2022 | ||
| WO-2023166155-A1 | A chimeric endolysin polypeptide | Inactive | 04-Mar-2022 | ||
| AU-2023227390-A1 | A chimeric endolysin polypeptide. | Pending | 04-Mar-2022 | C12N9/2462 |
Micreos Group Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Micreos Group Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Horizon 2020 | Government | |||
| Dutch Ministry of Economic Affairs | Government | |||
| Oost NL | Venture Capital | Minority | ||
| Partners in Equity | Impact Investing | Minority | ||
| Altria Group | Corporation | Minority |
Micreos Group FAQs
-
When was Micreos Group founded?
Micreos Group was founded in 2005.
-
Where is Micreos Group headquartered?
Micreos Group is headquartered in Bilthoven, Netherlands.
-
What is the size of Micreos Group?
Micreos Group has 6 total employees.
-
What industry is Micreos Group in?
Micreos Group’s primary industry is Holding Companies.
-
Is Micreos Group a private or public company?
Micreos Group is a Private company.
-
What is Micreos Group’s current revenue?
The current revenue for Micreos Group is .
-
How much funding has Micreos Group raised over time?
Micreos Group has raised $103M.
-
Who are Micreos Group’s investors?
Horizon 2020, Dutch Ministry of Economic Affairs, Oost NL, Partners in Equity, and Altria Group are 5 of 6 investors who have invested in Micreos Group.
-
Who are Micreos Group’s competitors?
Gangagen Biotechnologies, UTILITY Therapeutics, Melinta Therapeutics, Spero Therapeutics, and Ability Pharma are some of the 10 competitors of Micreos Group.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
